Search

1 to 10 of 160
Sort by

Library Entry
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article seeking to analyze the early immunogenomic changes in ESCC induced by CCRT and to correlate them with clinical outcomes. The results provide a potential basis for combining immunotherapy with CCRT for the...


Library Entry
Advances in Cancer Immunotherapy™ Webinar Series: Updates from the Field - Clinical Updates from SITC 2018 (Presentation Slides)

This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers Christian M. Capitini, MD, and Zachary S. Morris,...

Advances in Cancer Immunotherapy Updates from the Field - Clinical Updates from SITC 2018.pdf


Event
SITC Cancer Immunotherapy Guidelines – Head and Neck Cancers Webinar

Join leading experts in cancer immunotherapy for the SITC Cancer Immunotherapy Guidelines – Head and Neck Cancers Webinar. This FREE CME-, CNE-, CPE-certified webinar is a chance for healthcare providers who treat cancer patients, including oncologists, physicians, disease specialists,...

 07-24-2019 | 15:00 - 16:00 ET



Library Entry
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a commentary performing a comparative analysis of two studies to identify potential factors in the control arm that can impact clinical trial bio-statistical outcomes and which may have implications for future immunotherapy clinical...


Library Entry
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article suggesting that IL-1α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs. Authors: Madelyn...